Navigation Links
R&D Spending by U.S. Biopharmaceutical Companies Reaches Record $58.8 Billion in 2007
Date:3/24/2008

WASHINGTON, March 24 /PRNewswire-USNewswire/ -- America's pharmaceutical and biotechnology research companies invested a record $58.8 billion last year in the research and development of new life-changing medicines and vaccines -- an increase of nearly $3 billion from 2006, according to analyses by the Pharmaceutical Research and Manufacturers of America (PhRMA) and Burrill & Company. The release of the report coincides with PhRMA's 50th anniversary, which it observes today.

This record R&D investment reflects the continued commitment of America's pharmaceutical research companies to lead the world in the pursuit of new, life-saving and life-enhancing medicines.

PhRMA-member companies alone spent an estimated $44.5 billion on pharmaceutical R&D last year -- up from the previous record of $43 billion in 2006, according to the PhRMA survey. The Burrill & Company analysis shows that non-PhRMA pharmaceutical research companies in the United States spent an estimated $14.3 billion on R&D last year, compared with $12.2 billion in 2006.

Investment in research and development by America's pharmaceutical research companies grew modestly last year, despite a challenging economic environment and a continuing sharp deceleration in drug spending growth. Although the rate of R&D growth was slower than in prior years, research spending as a percentage of sales remained high. Over the past seven years, America's pharmaceutical research companies have consistently invested around 18 percent of sales on R&D activities.

As in past years, there are an increasing number of potential new drugs entering clinical testing. Today, there are more than 2,700 medicines in development in the U.S. for nearly 4,600 different indications. Five years ago, there were about 2,000 medicines in development.

U.S. pharmaceutical companies' dedication to research has been observed by many independent, objective experts. For instance, the nonpartisan Congr
'/>"/>

SOURCE Pharmaceutical Research and Manufacturers of America
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
2. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
3. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
4. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
5. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
6. Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG
7. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
8. Morria Biopharmaceuticals Plc Announces Appointment of Dr. Rosemary Mazanet as Interim Chief Executive Officer
9. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
10. Morria Biopharmaceuticals Plc Appoints Dr. Johnson Lau and Dr. David Sidransky to Board of Directors
11. XTL Biopharmaceuticals Ltd. AGM / EGM Postponed Until October 2, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... On behalf of biotech client GenScript ... Goldman & Spitzer, P.A. (Wilentz) secured a significant jury ... in excess of $10 million. The jury determined that ... that it improperly hired one or more of GenScript,s ... judgment notwithstanding the verdict, a new trial, and remittitur. ...
(Date:2/26/2015)... Feb. 26, 2015 Protiviti ( www.protiviti.com ), ... of the Governance Portal , designed to increase ... compliance (GRC) tasks across multiple business units and projects. ... help customers better align their controls with the COSO ... ) requirements. In response to client feedback, Protiviti has ...
(Date:2/26/2015)... , Feb. 26, 2015 The healthcare landscape is ... arena, Frost & Sullivan will host its 20 th ... MindXchange , March 8 to 10, at the Hilton San ... This event is a platform for ... to discuss industry disruptions and how to succeed in an ...
(Date:2/26/2015)... (PRWEB) February 26, 2015 RURO, Inc., ... released FreezerPro® version 6.2 – the latest update to ... reputation is that of a quick and easy method ... With the latest version, RURO engineering has enhanced the ... to move large amounts of sample records. , ...
Breaking Biology Technology:Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3Protiviti Governance Portal Helps Companies Drive Governance, Risk and Compliance Productivity Across Multiple Business Units 2Protiviti Governance Portal Helps Companies Drive Governance, Risk and Compliance Productivity Across Multiple Business Units 3Embrace the Future of Medical Technologies with Frost & Sullivan 2Embrace the Future of Medical Technologies with Frost & Sullivan 3RURO Releases FreezerPro® version 6.2 2
... Science ... ... -- DuPont was named the 2009 recipient of the Corporate Innovation Award by the ... that has made a substantial difference in the marketplace and global community., , , ...
... experiment by college students that will study how microbes grow ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20081007/38461LOGO ) , ... developed the experiment that will fly as part of the ... p.m. EST on Nov. 16 from NASA,s Kennedy Space Center ...
... 12 Hollis-Eden Pharmaceuticals, Inc. (Nasdaq: HEPH ), ... I/II open-label dose-ranging trial with Apoptone® (HE3235) for hormone-resistant ... on November 16 at the American Association for Cancer ... Boston. Apoptone, a novel steroid that is an ...
Cached Biology Technology:DuPont Receives Corporate Innovation Award 2DuPont Receives Corporate Innovation Award 3DuPont Receives Corporate Innovation Award 4Students Send Microbe Experiment on Space Shuttle Atlantis 2Students Send Microbe Experiment on Space Shuttle Atlantis 3Hollis-Eden to Present Interim Data From Its Phase I/II Clinical Studies of Apoptone(R) (HE3235) at Molecular Targets and Cancer Therapeutics Conference 2Hollis-Eden to Present Interim Data From Its Phase I/II Clinical Studies of Apoptone(R) (HE3235) at Molecular Targets and Cancer Therapeutics Conference 3Hollis-Eden to Present Interim Data From Its Phase I/II Clinical Studies of Apoptone(R) (HE3235) at Molecular Targets and Cancer Therapeutics Conference 4Hollis-Eden to Present Interim Data From Its Phase I/II Clinical Studies of Apoptone(R) (HE3235) at Molecular Targets and Cancer Therapeutics Conference 5
(Date:2/11/2015)... , February 11, 2015 ... report "Access Control Market by Product (Cards and Readers, ... Military and Defense, Government, Industrial, Healthcare, Education) and By ... by MarketsandMarkets, the Access Control Market is ... growing at a CAGR of 10.6% between ...
(Date:2/9/2015)... , Feb. 9, 2015  Lintec of America recently ... for carbon nanotube (CNT) macrostructures, including sheets, yarns and ... (UTD). Leveraging the vast industrial resources of ... Japan , Lintec of America is forming the ... TX , focusing on scaling up the manufacturing ...
(Date:2/5/2015)... , Feb. 5, 2015  Marken is starting ... company and has launched a new marketing campaign to ... Organization (CLO).  The new campaign focuses on First ... protocol and shipments. The first headline in ... aligns Marken,s priorities with its client,s priorities. Marken recognizes ...
Breaking Biology News(10 mins):Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Marken Launches New Patient-Centric Campaign 2
... immune system's pro-inflammatory response to bacterial invasion is ... called inducible nitric oxide synthase. In a study ... report that the predominantly anti-inflammatory enzyme, endothelial nitric ... production in response to infection. This discovery may ...
... Until now it has been impossible to accurately measure ... in real time and at the level of a ... Plant Biology and Stanford University are the first to ... molecular sensors to view changes in brain chemical levels. ...
... (MGH) has identified 80 new genes essential to the ... tool for inactivating genes in plants or animals. They ... that participate in the gene-silencing mechanism, which someday may ... in the journal Science and is receiving early online ...
Cached Biology News:Researchers report new pro-inflammatory role for anti-inflammatory enzyme 2Revolutionary nanotechnology illuminates brain cells at work 2Revolutionary nanotechnology illuminates brain cells at work 3Scientists identify genetic pathways essential to RNA interference 2Scientists identify genetic pathways essential to RNA interference 3
... PROTEAN II xi multi-cell is for 2-D separations. ... cooling capabilities. The PROTEAN II xi multi-cell can ... type of glass plates, and cooling system. The ... to the PROTEAN II XL multi-cell for a ...
F40 piston seals are supplied as 2 seals with a seal tool to service one F40 pump of a BioLogic DuoFlow workstation....
... probe for DNA. Binds to the minor ... rich DNA), forming a stable complex which ... alone. DAPI is several times more sensitive ... agarose gels. It may be used for ...
Mol wt: monoisotopic mol wt1,045.5423 Da by calculation...
Biology Products: